Allogeneic platforms

Allogeneic T cell CAR platforms:

Not every patient has robust T cells that permit the use of autologous cells for CAR therapy.  The development of technologies that enable the use of healthy allogeneic T cells as a source of CAR effector cells while avoiding potential Graft-versus-Host-Disease (GVHD) would improve the manufacturing and affordability of CAR cell therapy.

We are developing TIM (T cell inhibitory molecules) technology to allow the use of CAR T cells without GVHD yet retain excellent therapeutic efficacy.